Canada and EU may extend MRA (mutual recognition agreement) transition period:
This article was originally published in Clinica
There may be a delay in the final implementation of the mutual recognition agreement (MRA) between Europe and Canada. The accord, which covers a number of sectors including medical devices, came into force on November 1 last year and a confidence building phase is now underway. This phase was expected to last 18 months. However, "an extension is likely as the implementation is complex", involving both the technical dossier review and quality systems, according to Dorothy Walker, the MRA co-ordinator for the Canadian Medical Devices Bureau.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.